UNASSIGNED: 2012 Background: Current standard of care for newly diagnosed @entity463 includes trimodality treatment followed by six cycles of adjuvant @entity2903 ( @entity2904 ). We analysed the uptake of standard of care in a real-world setting, and compared outcome to updated controlled clinical trial data. METHODS: All @entity463 @entity1 registered with @entity5 Care Ontario between 2004-2008 were identified. Those who were >= 16 years age, newly diagnosed, treated at our institution, had confirmed pathology, complete records and imaging,were included. Demographics, planned and delivered treatments, total cycles of adjuvant @entity2904 , @entity137 and outcome were captured. For survival analysis @entity1 were stratified by age, ECOG, and treatment modalities, including total cycles of @entity2904 delivered. Descriptive statistics were used for early progressors and long term survivors. Kaplan-Meier curves, log-rank test and Cox proportional hazards model were used for survival analyses. To compare outcome from our population database to published data from controlled clinical trials, @entity1 were stratified into radiotherapy (RT) only group or concurrent chemoradiation (CRT) followed by @entity2904 . At a median follow-up of 28 months, we compared our outcome data to updated EORTC 22981/26981 NCIC CE. 3 results. RESULTS: 517 @entity1 were identified and 433 included for analysis. Majority were male (63%), ECOG 0-1 (66%), and <=65 years(55%). 44% received CRT followed by @entity2904 , 13% had CRT only, 30% had RT only and 13% had best supportive care. 35% had >6 cycles of @entity2904 , 10% were early progressors (<3 months from completing CRT) and 9% survived beyond 2 years. In the entire cohort poor ECOG or older age demonstrated inferior survival (p<0.0001, p=0.0003 respectively). In a multivariate analysis CRT followed by @entity2904 predicted superior survival (p<0.0001). Comparison of our results to EORTC 22981/26981 NCIC CE. 3 data showed median survival was 15.8 months vs. 14.6 months, 2 year survival rate for CRT plus @entity2904 was 35% vs. 26%, and for RT alone 0% vs. 10%, respectively. CONCLUSIONS: Our results show that only < 50% of @entity463 @entity1 complete standard of care in the real-world setting and prognosis remains dismal for @entity1 who do not receive CRT.

A population-based study of XXXX ( @entity463 ) in the new stupp paradigm: Have we improved outcome?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer'] @entity2904 :: ('CHEBI:72564', 'Chemical') :: ['TMZ'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity463 :: ('MESH:D005909', 'Disease') :: ['GBM']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma multiforme']
